APELOA has obtained FDA approval for our Metoprolol Succinate Extended-Release Tablets. This milestone underscores our capability to bring the U.S. market high-quality medication, reinforcing our commitment to global healthcare.
Metoprolol Succinate, a selective β1 receptor blocker, is essential in treating hypertension, angina, and chronic heart failure. Our product's FDA approval follows its successful NMPA clearance in 2021 and recognition in China's national drug procurement, enhancing our market presence and brand reputation.
The recent zero-defect PAI by the U.S. FDA at our international manufacturing facility in 2023 is a testament to our stringent quality standards. APELOA continues to drive our internationalization strategy, dedicated to bringing more innovative formulations to the global market, aiming to improve medication safety and accessibility for patients worldwide.
